AnaptysBio, Inc. (ANAB)
NASDAQ · Manufacturing · Pharmaceutical preparations
$51.00−$0.7000 (−1.35%) on the dayAs of the close; data may be delayed.
ANAB price, last 12 months
Key stats
- Previous close
- $51.70
- Open
- $52.38
- Day range
- $50.80 – $52.38
- 52-week range
- $20.79 – $73.30
- Volume
- 437.4K
- Avg volume (20 days)
- 534.5K
- Market cap
- $1.5B
Performance
1W−7.6%
1M−12.1%
3M−19.2%
6M−21.5%
YTD+5.2%
1Y+130.4%
vs S&P 500, 1Y+113.6 pts
Technicals and fundamentals
About AnaptysBio, Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $1.5B